- Home
- OLO vs GYRE Comparison
OLO vs GYRE Comparison
Compare OLO & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLO
- GYRE
- Stock Information
- Founded
- OLO 2005
- GYRE 2002
- Country
- OLO United States
- GYRE United States
- Employees
- OLO N/A
- GYRE N/A
- Industry
- OLO Major Banks
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- OLO Finance
- GYRE Health Care
- Exchange
- OLO Nasdaq
- GYRE Nasdaq
- Market Cap
- OLO 1.3B
- GYRE 1.3B
- IPO Year
- OLO 2021
- GYRE N/A
- Fundamental
- Price
- OLO $7.82
- GYRE $11.14
- Analyst Decision
- OLO Strong Buy
- GYRE
- Analyst Count
- OLO 3
- GYRE 0
- Target Price
- OLO $8.33
- GYRE N/A
- AVG Volume (30 Days)
- OLO 1.8M
- GYRE 144.6K
- Earning Date
- OLO 02-19-2025
- GYRE 11-13-2024
- Dividend Yield
- OLO N/A
- GYRE N/A
- EPS Growth
- OLO N/A
- GYRE N/A
- EPS
- OLO N/A
- GYRE N/A
- Revenue
- OLO $271,872,000.00
- GYRE $105,033,000.00
- Revenue This Year
- OLO $24.31
- GYRE $25.32
- Revenue Next Year
- OLO $15.65
- GYRE $12.95
- P/E Ratio
- OLO N/A
- GYRE N/A
- Revenue Growth
- OLO 26.41
- GYRE N/A
- 52 Week Low
- OLO $4.20
- GYRE $8.26
- 52 Week High
- OLO $8.18
- GYRE $30.39
- Technical
- Relative Strength Index (RSI)
- OLO 65.67
- GYRE 47.54
- Support Level
- OLO $7.52
- GYRE $9.61
- Resistance Level
- OLO $8.18
- GYRE $12.94
- Average True Range (ATR)
- OLO 0.35
- GYRE 1.17
- MACD
- OLO -0.05
- GYRE 0.13
- Stochastic Oscillator
- OLO 65.55
- GYRE 47.06
About OLO Olo Inc.
Olo Inc is an open Software as a Service platform for restaurants. Its platform powers restaurant brands' on-demand digital commerce operations, enabling digital ordering, delivery, front-of-house management, and payments, while further strengthening and enhancing restaurants' direct guest relationships. The company generates revenue from providing its customers access to its platform.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.